Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault.

Sarepta Therapeutics' stock rallied sharply after the FDA lifted its voluntary pause on Elevidys shipments for Duchenne muscular dystrophy patients, confirming one patient death previously linked to the drug was unrelated. This positive development, which saw shares gain 17.4% on Monday following a 16.2% rally Friday, removes a significant overhang for the company. However, analysts caution that Sarepta still faces substantial hurdles in restoring patient and physician confidence after a series of negative events and a dramatic 88.9% stock depreciation in 2025.

Analysis

Sarepta Therapeutics has received a significant positive catalyst after the FDA concluded a patient death was unrelated to its Duchenne muscular dystrophy (DMD) drug, Elevidys, and subsequently cleared the company to resume shipments. This news triggered a sharp rally, with the stock gaining 17.4% in one session, building on a 16.2% rise from the previous day. However, this relief follows a period of substantial negative developments, including other patient deaths, large job cuts, and a wider-than-expected quarterly loss. The severity of the company's situation is underscored by its stock's performance; despite the recent gains, it is on track for an eighth consecutive monthly decline and has plummeted 88.9% in 2025, eroding its market capitalization from $11.8 billion to $1.6 billion. This performance is in stark contrast to the iShares Biotechnology ETF's 1.2% gain and the S&P 500's 8.4% advance. Analysts from J.P. Morgan and Oppenheimer, who both recently upgraded the stock after prior downgrades, reflect the market's whiplash sentiment but remain cautious, highlighting that it could take several quarters to restore confidence among doctors and patients and to understand the drug's uptake trajectory in what they term an "unprecedented" regulatory situation.

Key Decisions for Investors

• The FDA's clearance represents a major de-risking event, potentially offering a speculative entry point for investors with high risk tolerance, but the stock's 88.9% year-to-date decline highlights the significant underlying challenges that remain.
• Investors should closely monitor Elevidys's initial sales and prescription data over the next two quarters, as this will be the primary indicator of whether patient and physician confidence is recovering, a key concern cited by analysts.
• Given the stock's sensitivity to safety news and the rapid reversals in analyst ratings, investors should be prepared for continued high volatility and consider the risk of further negative headlines which could quickly erase recent gains.
• The stock's severe underperformance relative to both the S&P 500 and the broader biotech sector ETF suggests the company's recovery is contingent on execution and successful commercial relaunch, not just market trends.